Contributor Disclosures for Pyoderma Gangrenosum

Role Name Disclosure Details Author  J Mark Jackson, MD, Assistant Clinical Professor, Department of Internal Medicine, Division of Dermatology, University of Louisville Nothing to disclose Details Coauthor  Jeffrey P Callen, MD, Professor of Medicine, Chief, Division of Dermatology, University of Louisville School of Medicine Amgen Abbott Electrical Optical Sciences Centocor Details Medical Editor  David P Fivenson, MD, Director, Wound Care Service, Department of Dermatology, Henry Ford Health System Nothing to disclose Details Pharmacy Editor  Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center Nothing to disclose Details Managing Editor  Warren R Heymann, MD, Head, Division of Dermatology, Professor, Department of Internal Medicine, University of Medicine and Dentistry of New Jersey Nothing to disclose Details CME Editor  Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Nothing to disclose Details Chief Editor  Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center Nothing to disclose Details Contributor Disclosure Contributor: Contributor Disclosure: J Mark Jackson, Author  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Jeffrey P Callen  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Amgen Honoraria Consulting   Abbott Honoraria Consulting   Electrical Optical Sciences Honoraria Consulting   Centocor Honoraria Consulting   Off label or investigational use of medication Each chapter has medications that are "off label" in each instance I have indicated the level of evidence that exists. Contributor Disclosure Contributor: Contributor Disclosure: David P Fivenson, Medical Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Michael J Wells  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Warren R Heymann, Managing Editor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Joel M Gelfand, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Dirk M Elston  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication